Cited by 406Cancer Immunotherapy and BiomarkersTGF-β signaling in diseasesImmunotherapy and Immune Responses

The DOI matches its Crossref record; 34 of the 35 references it cites were found in a registry or an index.

Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors

Open access

Strauss, Julius, Heery, Christopher R., Schlom, Jeffrey, Madan, Ravi A., Cao, Liang, Kang, Zhigang, Lamping, Elizabeth, Marté, Jennifer L., Donahue, Renee N., Grenga, Italia, Cordes, Lisa, Christensen, Olaf, Mahnke, Lisa, Helwig, Christoph, Gulley, James L.·2018·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-17-2653PMC PMC7985967

Published version of a preprint

Open this paper in CoChat — free account

Abstract

Purpose: M7824 (MSB0011359C) is an innovative first-in-class bifunctional fusion protein composed of a mAb against programmed death ligand 1 (PD-L1) fused to a TGFβ “trap.” Experimental Design: In the 3+3 dose-escalation component of this phase I study (NCT02517398), eligible patients with advanced solid tumors received M7824 at 1, 3, 10, or 20 mg/kg once every 2 weeks until confirmed progression, unacceptable toxicity, or trial withdrawal; in addition, a cohort received an initial 0.3 mg/kg dose to evaluate pharmacokinetics/pharmacodynamics, followed by 10 mg/kg dosing. The primary objective is to determine the safety and maximum tolerated dose (MTD); secondary objectives include pharmacokinetics, immunogenicity, and best overall response. Results: Nineteen heavily pretreated patients with ECOG 0–1 have received M7824. Grade ≥3 treatment-related adverse events occurred in four patients (skin infection secondary to localized bullous pemphigoid, asymptomatic lipase increase, colitis with associated anemia, and gastroparesis with hypokalemia). The MTD was not reached. M7824 saturated peripheral PD-L1 and sequestered any released plasma TGFβ1, -β2, and -β3 throughout the dosing period at >1 mg/kg. There were signs of efficacy across all dose levels, including one ongoing confirmed complete response (cervical cancer), two durable confirmed partial responses (PR; pancreatic cancer; anal cancer), one near-PR (cervical cancer), and two cases of prolonged stable disease in patients with growing disease at study entry (pancreatic cancer; carcinoid). Conclusions: M7824 has a manageable safety profile in patients with heavily pretreated advanced solid tumors. Early signs of efficacy are encouraging, and multiple expansion cohorts are ongoing in a range of tumors. Clin Cancer Res; 24(6); 1287–95. ©2018 AACR.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-17-2653

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Weber, J. S., D’Angelo, S. P., Minor, D. R., Hodi, F. S., Gutzmer, R., Neyns, B., Höeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,725

Show all 35 references

Sorted by citations

Items 301–400 of 406

Atezolizumab: an investigational agent for the treatment of biliary tract cancer
Hack, S. P., & Zhu, A. X. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1974838 · Cited by 8
Rational Combinations of Targeted Therapy and Immune Checkpoint Inhibitors in Head and Neck Cancers
Chai, A. W. Y., Yee, P. S., & Cheong, S. C. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.837835 · Cited by 8
Treating Biliary Tract Cancers: New Targets and Therapies
Ho, J. K., Fiocco, C., & Spencer, K. R. (2022) · Drugs · doi:10.1007/s40265-022-01808-x · Cited by 8
New avenues for the treatment of immunotherapy-resistant pancreatic cancer
Silva, L. G. D. O., Lemos, F. F. B., Luz, M. S., Pinheiro, S. L. R., Calmon, M. S., Santos, G. L. C., Rocha, G. R., & de Melo, F. F. (2024) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v16.i4.1134 · Cited by 7
Next-generation immunotherapy for solid tumors: combination immunotherapy with crosstalk blockade of TGFβ and PD-1/PD-L1
Quach, H. T., Hou, Z., Bellis, R. Y., Saini, J. K., Amador-Molina, A., Adusumilli, P. S., & Xiong, Y. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2152323 · Cited by 8
A novel bispecific peptide targeting PD-1 and PD-L1 with combined antitumor activity of T-cells derived from the patients with TSCC
Wang, L., Zheng, J., Tan, Z., Zhang, Y., & Wang, H. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112582 · Cited by 7
Efficacy and safety of bintrafusp alfa in 2 phase I expansion cohorts with advanced HCC
Lim, H. Y., Heo, J., Peguero, J. A., Ryoo, B., Decaens, T., Barlési, F., Moehler, M. H., Jehl, G., Eggleton, S. P., Bajars, M., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000001054 · Cited by 7
Self-citation
Research progress on tumor-infiltrating lymphocyte therapy for cervical cancer
Zhang, W., Liu, Y., Li, D., Liu, S., Cai, X., Tang, J.-Y., Zuo, Z., Li, X., & Zhao, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1524842 · Cited by 9
Immunogenomic Landscape and Immune-Related Gene-Based Prognostic Signature in Asian Gastric Cancer
Mao, C., Ma, L., Huang, Y., Yang, X., Huang, H., Cai, W., Sitrakiniaina, A., Gu, R., Xue, X., & Shen, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.750768 · Cited by 7
Emerging Therapies in Penile Cancer
Alencar, A. M., & Sonpavde, G. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.910335 · Cited by 7
Identification of HMGA2 as a predictive biomarker of response to bintrafusp alfa in a phase 1 trial in patients with advanced triple-negative breast cancer
Spira, A. I., Awada, A. H., Isambert, N., Lorente, D., Penel, N., Zhang, Y., Ojalvo, L. S., Hicking, C., Rolfe, A., Ihling, C. H., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.981940 · Cited by 7
PD-L1 Inhibitors for the Treatment of Prostate Cancer
Santoni, M., Massari, F., Liang Cheng, C., Cimadamore, A., Scarpelli, M., Montironi, R., & Antonio Lopez-beltran, B. (2020) · Current Drug Targets · doi:10.2174/1389450121666200609142219 · Cited by 7
Setting up clinical trials for success: Applying preclinical advances in combined TGFβ/PD‐L1 inhibition to ongoing clinical studies
Strait, A. A., & Wang, X. (2021) · Molecular Carcinogenesis · doi:10.1002/mc.23373 · Cited by 7
Short-term cultured tumor fragments to study immunotherapy combinations based on CD137 (4-1BB) agonism
Eguren‐Santamaría, I., Rodríguez, I., Herrero, C., de Piérola, E. F., Azpilikueta, A., Sánchez‐Gregorio, S., Bolaños, E., Gomis, G., Molero-Glez, P., Chacón, E., et al. (2024) · OncoImmunology · doi:10.1080/2162402x.2024.2373519 · Cited by 6
The Landscape of Bispecific Antibodies in Solid Tumor Oncology: Trends, Challenges, and Opportunities
ElBeblawy, R., Jani, C., Pérez‐Granado, J., Gramling, M., & Desai, A. P. (2025) · Cancer Medicine · doi:10.1002/cam4.71432 · Cited by 9
Spatial single-cell multi-omics characterization of the tumor microenvironment heterogeneity by HER-2 expression status in gastric cancer
Peng, H., Chen, Y., Yao, Q., Liang, Y., Chong, X., Luo, Y., Liu, D., Wang, Y., Li, Y., Feng, X., et al. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02577-x · Cited by 6
First-line treatment with KN046, chemotherapy and palliative radiotherapy for advanced esophageal squamous cell carcinoma: an open-label, dose escalation, and dose expansion phase Ib trial
Zhao, Q., Su, X., Xue, J., Liu, Y., Zhu, J., Cai, X., & Qin, S. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03769-4 · Cited by 8
The prognostic role of soluble transforming growth factor‐β and its correlation with soluble programmed death‐ligand 1 in biliary tract cancer
Kim, J. W., Lee, K., Kim, J., Suh, K. J., Nam, A., Bang, J., Jin, M. H., Oh, K.-S., Kim, J., Kim, T., et al. (2020) · Liver International · doi:10.1111/liv.14636 · Cited by 6
Resistance to Immunotherapy: Mechanisms and Means for Overcoming
Salkeni, M. A., Shin, J. Y., & Gulley, J. L. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-79308-1_2 · Cited by 6
Self-citation
Scientifically based combination therapies with immuno‐oncology checkpoint inhibitors
Chew, H. Y., Dolcetti, R., & Simpson, F. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14338 · Cited by 6
Next Generation Therapeutic Strateg‐Es: Evolving cancer immunotherapy through agents that Engage, Expand and Enable the anti‐tumor immune response
Wolfson, B., & Hodge, J. W. (2021) · ImmunoMedicine · doi:10.1002/imed.1020 · Cited by 6
Diverse and precision therapies open new horizons for patients with advanced pancreatic ductal adenocarcinoma
Bai, R.-L., Wang, N.-Y., Zhao, L., Zhang, Y., & Cui, J. (2021) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2021.08.012 · Cited by 6
The Challenges and Future of Immunotherapy for Gliomas
Wu, A., & Lim, M. K. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000544 · Cited by 6
Analysis of the tumor microenvironment and anti-tumor efficacy of subcutaneous vs systemic delivery of the bifunctional agent bintrafusp alfa
Ozawa, Y., Hicks, K. C., Minnar, C. M., Knudson, K. M., Schlom, J., & Gameiro, S. R. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1915561 · Cited by 6
Self-citation
Feasibility IB trial of paclitaxel/carboplatin + Galunisertib. (a small molecule inhibitor of the kinase domain of type 1 TGF-B receptor) in patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovary
Washington, C., Dwivedi, S. K. D., Gunderson-Jackson, C., Walker, J. L., Mannel, R. S., Holman, L. L., Richardson, D. L., Neelakantan, D., Cohoon, A. J., Ding, K., et al. (2025) · Gynecologic Oncology · doi:10.1016/j.ygyno.2025.10.021 · Cited by 5
Unravelling the crosstalk of Hedgehog with Wnt, Notch and TGF-β signaling pathways
Sreeshma, B., Varshini, M. A., Patni, A. P., & Devi, A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-18800-8.00001-0 · Cited by 5
A chronic signaling TGFb zebrafish reporter identifies immune response in melanoma
Noonan, H. R., Thornock, A., Barbano, J., Xifaras, M. E., Baron, C. S., Yang, S. P., Koczirka, K., McConnell, A. M., & Zon, L. I. (2024) · eLife · doi:10.7554/elife.83527 · Cited by 5
Bispecific therapeutics: a state-of-the-art review on the combination of immune checkpoint inhibition with costimulatory and non-checkpoint targeted therapy
Mortaheb, S., Pezeshki, P. S., & Rezaei, N. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2426636 · Cited by 5
Cytokine Therapy in Bladder Cancer: Mechanisms, Efficacy, and Future Prospects
Oyler, H. J., Bruton, L. G., Maher, A. J., Yu, D., Shely, N. W., Wakefield, M. R., & Fang, Y. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47040278 · Cited by 5
Single-cell analysis reveals CD34+CD90+ endothelial cells promote tumor metastasis in gallbladder cancer
Hou, M., Chen, J., Jiang, Y., Liu, C., Wang, X., Liu, E., Zong, Y., Gu, M., Meng, Z., Wang, S., et al. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01040-2 · Cited by 6
Les anticorps etscaffoldbispécifiques, des médicaments innovants en oncologie impliquant le ciblage des cellules immunitaires
Chames, P., & Wurch, T. (2019) · médecine/sciences · doi:10.1051/medsci/2019242 · Cited by 5
Inhibiting TGF-β signaling pathway for disease therapy: challenges and opportunities
Gao, X., Li, X., Zhang, C., Zhou, J., Gu, K., Liu, X., & Bai, C. (2025) · Cytokine · doi:10.1016/j.cyto.2025.157048 · Cited by 4
Advancing immunotherapy for intrahepatic cholangiocarcinoma: exploring the tumor immune microenvironment and innovative treatments
Wei, P., & Zhao, L. (2024) · Hepatoma Research · doi:10.20517/2394-5079.2024.72 · Cited by 5
Bispecific Antibodies in Colorectal Cancer Therapy: Recent Insights and Emerging Concepts
Ghalamfarsa, F., Khatami, S. H., Vakili, O., Taheri‐Anganeh, M., Tajbakhsh, A., Savardashtaki, A., Fazli, Y., Uonaki, L. R., Shabaninejad, Z., Movahedpour, A., et al. (2021) · Immunotherapy · doi:10.2217/imt-2021-0107 · Cited by 5
Transforming growth factor-β1 and soluble co-inhibitory immune checkpoints as putative drivers of immune suppression in patients with basal cell carcinoma
Kgokolo, M., Malinga, N. Z., Steel, H. C., Meyer, P. W. A., Smit, T., Anderson, R., & Rapoport, B. L. (2024) · Translational Oncology · doi:10.1016/j.tranon.2023.101867 · Cited by 4
An evaluation of avelumab for the treatment of genitourinary tumors
Stühler, V., Maas, J. M., Walz, S., Stenzl, A., & Bedke, J. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1769596 · Cited by 4
Severe recalcitrant morbilliform eruption from dual immune checkpoint blockade
Fatima, S., Veenstra, J. J., Antonyan, A. S., & Kohen, L. L. (2018) · JAAD Case Reports · doi:10.1016/j.jdcr.2018.05.001 · Cited by 4
Molecular-targeted Therapy for Precision Medicine in Gastrointestinal Cancer: Advancement in Cancer Targeting Strategies
Deshmukh, R., Verma, S., Yaduwanshi, P. S., Dubey, A., & Kumari, M. (2025) · Current Cancer Drug Targets · doi:10.2174/0115680096333058241114064802 · Cited by 5
Advances of bispecific antibodies using/application in dermatology: a review
Zhang, T., Yang, J., Liew, P. X., Zhang, Y., & Zhao, Z. (2025) · Frontiers in Allergy · doi:10.3389/falgy.2025.1668931 · Cited by 3
Advances in the application of PD-1/PD-L1 immunotherapy for prostate cancer: a review
Hu, G., Li, Z., Chen, Y., Liao, H., & Zhou, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1664587 · Cited by 3
The quadruple immunotherapy for colorectal cancer (QuICC) trial for mismatch repair-proficient metastatic colorectal cancer
Bracken-Clarke, D. M., Pastor, D. M., Marté, J. L., Donahue, R. N., Hodge, J. W., Cordes, L. M., Floudas, C. S., Tschernia, N. P., Karzai, F. H., Brownell, I., et al. (2026) · The Oncologist · doi:10.1093/oncolo/oyag008 · Cited by 3
Self-citation
Potent antitumor activity through dual targeting of PD-L1 and TGF-β pathways in the glioma tumor microenvironment
Silginer, M., Weller, M., Becher, B., Mastall, M., Weiß, T., Núñez, N. G., Kienzler, J. C., & Roth, P. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011824 · Cited by 3
Laryngeal squamous cell carcinoma: a functional “two-hit” model of papillomavirus–Epstein–Barr virus synergistic carcinogenesis
Wang, F., & Huangfu, H. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1768893 · Cited by 3
Therapeutic Strategies Targeting the Tumor–Stromal Microenvironment in Colorectal Cancer: A Narrative Review
Heilijgers, F., Bakker, M.-C., van Hest, B., Franken, I. A., Speetjens, F. M., Peeters, K. C. M. J., Roodhart, J. M. L., & Mesker, W. E. (2026) · Targeted Oncology · doi:10.1007/s11523-026-01220-5 · Cited by 4
Next-generation cancer treatment: exploring the tumor microenvironment and CAR-T cell therapy potential
Bisola, M.-A. I., Ogieuhi, I. J., Ajekiigbe, V. O., Adegbola, M. O., Udojike, C., Adeshina, G. A., Ogidan, A. O., Mohamed, R. G. H., Woldehana, N. A., Akingbola, A., et al. (2025) · Discover Medicine · doi:10.1007/s44337-025-00253-5 · Cited by 3
JCSE01.05 Biomarker in Immunotherapy: Myth or Reality?
Addeo, A. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.08.265 · Cited by 3
Multiple Protein Biomarkers and Different Treatment Strategies for Colorectal Carcinoma: A Comprehensive Prospective
Chakraborty, B., Agarwal, S., Kori, S. K., Das, R., Kashaw, V., Iyer, A. K., & Kashaw, S. K. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867330666230505165031 · Cited by 3
Two Complementarity Immunotherapeutics in Non-Small-Cell Lung Cancer Patients—Mechanism of Action and Future Concepts
Wojas‐Krawczyk, K., Krawczyk, P. A., Gil, M., & Strzemski, M. (2021) · Cancers · doi:10.3390/cancers13112836 · Cited by 3
Immuno-genomic PanCancer Landscape Reveals Diverse Immune Escape Mechanisms and Immuno-Editing HistoriesPreprint
Mizuno, S., Yamaguchi, R., Hasegawa, T., Hayashi, S., Fujita, M., Zhang, F., Koh, Y., Lee, S., Yoon, S., Shimizu, E., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/285338 · Cited by 3
Recent advances in targeted and immunotherapeutic strategies for cholangiocarcinoma: A comprehensive review
Lin, X.-Y., Zhou, J.-B., Yonemori, K., Zhang, X., Ruan, J., & Jia, Y.-L. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2026.102124 · Cited by 3
Trispecific antibodies in cancer therapy: Mechanisms, clinical progress and future directions
Liu, X., Fan, X., Wang, Y., Wang, L., Lu, D., Wang, Y., Meng, X., Fan, L., Zhu, W., Liu, X., et al. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116503 · Cited by 2
Treg-directed cancer immunotherapy beyond immune checkpoints: progress and opportunities
Xie, J., Hamdy, H., & Elkord, E. (2026) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2026.03.007 · Cited by 2
Phase I study of Y101D, a bispecific antibody targeting PD-L1 and TGF-β in patients with advanced solid tumors
Sun, H., Chen, G., Xue, J. J., Zhang, Y. X., Ma, Y. X., Yang, Y., Fang, W., Zhao, Y., Huang, Y., Hong, S., et al. (2026) · The Oncologist · doi:10.1093/oncolo/oyag133 · Cited by 2
Study on the application value of fluorescent laparoscopy in pancreatic tumor surgery
Xi, S., Zhang, W., Qian, D., He, C., Zuo, X., Cai, J., Li, L., Cai, H., Akhil, C., & Wang, X. (2023) · Gland Surgery · doi:10.21037/gs-23-331 · Cited by 2
The Therapeutic Potential of Targeting Tumor Microenvironment and Modulation of Immunotherapy in Gastrointestinal Cancer
Sokhangouy, S. K., Jamialahmadi, H., Sani, M. S. M., Khalili‐Tanha, G., Rouzbahani, A. K., Mahmoudvand, G., Goudarzi, Z., Fakouri, A., Farokhi, S., Hassanian, S. M., et al. (2024) · Current Cancer Drug Targets · doi:10.2174/0115680096319027240820055043 · Cited by 2
Risk assessment of drug–drug interaction potential for bintrafusp alfa with cytochrome P4503A4 substrates: A totality of evidence approach
Vugmeyster, Y., Locke, G., Helwig, C., Rolfe, A., Dong, J. Q., & Venkatakrishnan, K. (2022) · Clinical and Translational Science · doi:10.1111/cts.13413 · Cited by 2
Self-citation
Mechanisms of Resistance and Strategies to Combat Resistance in PD-(L)1 Blockade
Moise, J., Murthy, J. J., Dabir, D., Yu, S., Kisto, F., Herron, E., & Aulakh, S. (2022) · Immuno · doi:10.3390/immuno2040041 · Cited by 2
The present and future of systemic and microenvironment-targeted therapy for pancreatic adenocarcinoma
Mehta, A., Hwang, W. L., & Weekes, C. D. (2020) · Annals of Pancreatic Cancer · doi:10.21037/apc-2020-pda-05 · Cited by 2
Efficacy and Safety of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting Transforming Growth Factor-β and Programmed Death-Ligand 1, Plus Chemotherapy in Patients With Stage IV NSCLC
Rolfo, C. D., Greillier, L., Veillon, R., Badin, F. B., Ghiringhelli, F., Isambert, N., Paulus, A., Chaudhary, S. P., Vugmeyster, Y., Sato, M., et al. (2024) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2024.100748 · Cited by 1
Antibody treatments for digestive cancers: Past, present, and future
Dadi, I., Mazard, T., Schmitt, L.-M., Chastel, T., Turtoï, A., Poul, M., & Pattingre, S. (2025) · Seminars in Oncology · doi:10.1016/j.seminoncol.2025.152369 · Cited by 1
Targeted Therapies Modulating Mesenchymal–Epithelial Transition-Linked Oncogenic Signaling in the Tumor Microenvironment: Comparative Profiling of Capmatinib, Bemcentinib, and Galunisertib
Kawczak, P., Feszak, I. J., & Bączek, T. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14196853 · Cited by 1
Unmasking cancer’s silent saboteurs: T regulatory cells as therapeutic targets in immunotherapy
Khudeir, J. F., & Elkord, E. (2025) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2025.2585521 · Cited by 2
The interplay between cytokines and immune checkpoints in breast cancer therapy
Wu, Y., Zhu, Y. F., Cang, Q., Shaibu, Z., Kong, L., Zhou, Q., Li, X., & Yin, L. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189539 · Cited by 1
TGF-β inhibition enhances anti-tumor immunity and sensitizes PD-1 blockade therapy of bone marrow-derived myofibroblasts-induced “immunotherapy resistance” tumor model
Cheng, X., He, L., Zhou, C., Li, Q., 张柏雯, Wang, J., Cheng, X., & Tu, S. (2026) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-026-04428-6 · Cited by 1
REMOVED: Severe recalcitrant cutaneous eruption with dual immune checkpoint blockade
Fatima, S., Veenstra, J. J., Antonyan, A. S., & Kohen, L. L. (2018) · JAAD Case Reports · doi:10.1016/j.jdcr.2017.10.004 · Cited by 1
Retracted
On the Immunotherapy for Tumors
Boyd, R. (2022) · Science Insights · doi:10.15354/si.22.re074 · Cited by 1
Improving Radiation Therapy in Pancreatic Cancer Through Radiosensitization Strategies
Dardare, J., Martz, N., Witz, A., Betz, M., Michel, C., Gilson, P., Merlin, J., Lambert, A., & Harlé, A. (2025) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2025.09.013 · Cited by 1
Neoadjuvante Therapie mit Bintrafusp alfa beim resektablen Cholangiokarzinom
Waidmann, O. (2020) · Forum · doi:10.1007/s12312-020-00828-6 · Cited by 1
Bintrafusp alfa and its unsuccessful development journey towards cervical cancer treatment
Nishio, S. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2541795 · Cited by 1
Developing Targeted Therapy against Pancreatic Cancer
Kaushik, G. (2019) · DigitalCommons@UNMC
Concluding Remarks
Xu, J., & Liu, M. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-3266-5_24
SMAD4 Inhibits CXCL1/CXCR2 to Trigger Antitumor Immunity in Colorectal CancerPreprint
Lian, B., Dong, T., You, N. Y., Wen, Y., & Wang, J. (2024) · Research Square · doi:10.21203/rs.3.rs-3912072/v1
TGF-β in tumor microenvironment, metabolism, and immunotherapy
Bai, H., & Wan, Y. Y. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13827-0.00017-2
Pharmacological targeting of PD-L1/PD-1 signaling in gynecological cancers
Farooqı, A. A., Özbey, G., Fayyaz, S., & Donfrancesco, C. (2025) · Postępy Higieny i Medycyny Doświadczalnej · doi:10.2478/ahem-2025-0004
The Immunoradiotherapy in HNSCC
Zhang, T., Du, W., Zhang, S.-X., Zhou, H., Bai, J., Xu, M., & Ma, X. (2025) · Springer eBooks · doi:10.1007/978-981-96-3659-4_4
Aktuelle Entwicklungen der Immuntherapie beim Pankreaskarzinom
Ellenrieder, V., & König, A. O. (2025) · Die Gastroenterologie · doi:10.1007/s11377-025-00910-2
Development of a nomogram integrating immune checkpoints, fibrosis indicators, and clinicopathological characteristics to predict overall survival in pancreatic cancer: a retrospective analysis
Qin, D., Huang, K., Yao, Z., Jiang, L., Zhu, Q., Cao, J., & Li, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1688440
Engineered multifunctional transforming growth factor-β type II receptor ectodomain fusions for oncology applications
Lenferink, A. E. G., Zwaagstra, J. C., Baardsnes, J., Delafosse, L., Parat, M., Iqbal, U., Lessard, E., Haqqani, A. S., Jezierski, A., Abu-Thuraia, A., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1648779
Additional file 4 of Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
Yi, M., Niu, M., Wu, Y., Ge, H., Jiao, D., Zhu, S., Zhang, J., Yan, Y., Zhou, P., Chu, Q., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21303575
Additional file 9 of Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
Yi, M., Niu, M., Wu, Y., Ge, H., Jiao, D., Zhu, S., Zhang, J., Yan, Y., Zhou, P., Chu, Q., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21303590
Additional file 15 of Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
Yi, M., Niu, M., Wu, Y., Ge, H., Jiao, D., Zhu, S., Zhang, J., Yan, Y., Zhou, P., Chu, Q., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21303563
Additional file 13 of Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
Yi, M., Niu, M., Wu, Y., Ge, H., Jiao, D., Zhu, S., Zhang, J., Yan, Y., Zhou, P., Chu, Q., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21303557
Additional file 2 of Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
Yi, M., Niu, M., Wu, Y., Ge, H., Jiao, D., Zhu, S., Zhang, J., Yan, Y., Zhou, P., Chu, Q., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21303569
Additional file 6 of Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
Yi, M., Niu, M., Wu, Y., Ge, H., Jiao, D., Zhu, S., Zhang, J., Yan, Y., Zhou, P., Chu, Q., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21303581
Additional file 14 of Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
Yi, M., Niu, M., Wu, Y., Ge, H., Jiao, D., Zhu, S., Zhang, J., Yan, Y., Zhou, P., Chu, Q., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21303560
Additional file 1 of The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1
Yi, M., Zhang, J., Li, A., Niu, M., Yan, Y., Jiao, Y., Luo, S., Zhou, P., & Wu, K. (2021) · Figshare · doi:10.6084/m9.figshare.14053438
Additional file 1 of Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
Yi, M., Niu, M., Wu, Y., Ge, H., Jiao, D., Zhu, S., Zhang, J., Yan, Y., Zhou, P., Chu, Q., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21303566
Additional file 1 of Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial
Liu, D., Zhou, J., Wang, Y., Li, M., Jiang, H., Liu, Y., Yin, X., Ge, M., Xiang, X., Ying, J., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21393828
Additional file 10 of Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
Yi, M., Niu, M., Wu, Y., Ge, H., Jiao, D., Zhu, S., Zhang, J., Yan, Y., Zhou, P., Chu, Q., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21303548
Additional file 5 of Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
Yi, M., Niu, M., Wu, Y., Ge, H., Jiao, D., Zhu, S., Zhang, J., Yan, Y., Zhou, P., Chu, Q., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21303578
Additional file 3 of Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
Yi, M., Niu, M., Wu, Y., Ge, H., Jiao, D., Zhu, S., Zhang, J., Yan, Y., Zhou, P., Chu, Q., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21303572
Additional file 12 of Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
Yi, M., Niu, M., Wu, Y., Ge, H., Jiao, D., Zhu, S., Zhang, J., Yan, Y., Zhou, P., Chu, Q., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21303554
Additional file 8 of Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
Yi, M., Niu, M., Wu, Y., Ge, H., Jiao, D., Zhu, S., Zhang, J., Yan, Y., Zhou, P., Chu, Q., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21303587
Additional file 7 of Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
Yi, M., Niu, M., Wu, Y., Ge, H., Jiao, D., Zhu, S., Zhang, J., Yan, Y., Zhou, P., Chu, Q., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21303584
Additional file 11 of Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors
Yi, M., Niu, M., Wu, Y., Ge, H., Jiao, D., Zhu, S., Zhang, J., Yan, Y., Zhou, P., Chu, Q., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21303551
Neue Hoffnung durch Immuntherapie?
König, A. O., & Ellenrieder, V. (2026) · InFo Hämatologie + Onkologie · doi:10.1007/s15004-026-1296-7
Development of a novel immune infiltration-based gene signature to predict prognosis and immunotherapy response of a novel anti-PD-L1/TGF-β bifunctional fusion protein in recurrent cervical cancer
Mao, Y., Xing, N., Sun, W., Bao, X., Liu, X., Wu, R., & Peng, J. (2026) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2026.2647560
Etude de l’influence du TGF-β sur les sous-populations de fibroblastes associés au cancer et leur implication pronostique dans les cancers du pancréas
Vienot, A. (2021) · theses.fr (ABES) · doi:10.70675/25d883b4z5eadz4f1bz93f0zcfa886c08e78
Study of septin 9 in the cell polarity and development of cholangiocarcinoma
Cai, T. (2022) · theses.fr (ABES) · doi:10.70675/c3888784z575bz4056z8b60z98cb8e7e8719
A bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β1 (SHR1701) enhanced preclinical antitumor activity in oral squamous cell carcinoma
Li, W., Fang, S., Cao, Y., Wang, Y., Kang, Z., He, Y., Cai, Y., Huang, Z., & Huang, Z. (2026) · Oral Oncology · doi:10.1016/j.oraloncology.2026.108078
Self-citation

Authors: Strauss, J., Heery, C. R., Schlom, J., Madan, R. A., Cao, L., Kang, Z., Lamping, E., Marté, J. L., Donahue, R. N., Grenga, I., Cordes, L., Christensen, O., Mahnke, L., Helwig, C., & Gulley, J. L.
Affiliations: National Institutes of Health (US)
7EMD Serono, Billerica, Massachusetts.
Merck KGaA, Darmstadt (Germany) (DE)
Corresponding author: Gulley, James L.
ORCID: Strauss, Julius
Schlom, Jeffrey
Madan, Ravi A.
Cao, Liang
Kang, Zhigang
Marté, Jennifer L.
Donahue, Renee N.
Cordes, Lisa
Helwig, Christoph
Gulley, James L.
Venue: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2018-03-14
Volume: 24
Issue: 6
Pages: 1287-1295
ISSN: 1078-0432 (ISSN-L)
1557-3265
DOI: 10.1158/1078-0432.ccr-17-2653
PMC: PMC7985967
OpenAlex: W2781947653
Cited by: 406
References: 35
Citations by year: 2026: 22 · 2025: 29 · 2024: 48 · 2023: 40 · 2022: 81 · 2021: 73 · 2020: 64 · 2019: 26 · 2018: 20
FWCI: 17.20
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Clinical Cancer Research (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (HHSN261200800001C)
National Cancer Institute (HHSN261200800001E), ZIABC010945)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: bifunctional fusion protein, PD-L1, TGF-β trap, TGF-β1, TGF-beta2, TGF-beta3, advanced solid tumors, maximum tolerated dose, safety, pharmacokinetics, immunogenicity, cervical cancer, pancreatic cancer, anal cancer, carcinoid tumor, dose escalation
MeSH terms: Antineoplastic Agents, Immunological, Adult, Aged, Combined Modality Therapy, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Neoplasm Staging, Neoplasms, Transforming Growth Factor beta, Treatment Outcome, Antibodies, Bispecific, Retreatment, Molecular Targeted Therapy, B7-H1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks